These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 2138080

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ, Jenner P.
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dopamine D2 receptor density remains constant in treated Parkinson's disease.
    Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW.
    Ann Neurol; 1986 May; 19(5):487-92. PubMed ID: 2940960
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors.
    Churchyard A, Donnan GA, Hughes A, Howells DW, Woodhouse D, Wong JY, Kalnins RM, Mendelsohn FA, Paxinos G.
    Ann Neurol; 1993 Aug; 34(2):219-26. PubMed ID: 8338346
    [Abstract] [Full Text] [Related]

  • 8. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease.
    Robertson HA.
    Trends Neurosci; 1992 Jun; 15(6):201-6. PubMed ID: 1378662
    [Abstract] [Full Text] [Related]

  • 9. Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline.
    Seeman P, Guan HC, Nobrega J, Jiwa D, Markstein R, Balk JH, Picetti R, Borrelli E, Van Tol HH.
    Synapse; 1997 Feb; 25(2):137-46. PubMed ID: 9021894
    [Abstract] [Full Text] [Related]

  • 10. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias.
    Robertson HA.
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):147-52. PubMed ID: 1349263
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
    Barbanti P, Fabbrini G, Ricci A, Cerbo R, Bronzetti E, Caronti B, Calderaro C, Felici L, Stocchi F, Meco G, Amenta F, Lenzi GL.
    Mov Disord; 1999 Sep; 14(5):764-71. PubMed ID: 10495037
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB, Bernardi G.
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [Abstract] [Full Text] [Related]

  • 16. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
    Joyce JN, Lexow N, Bird E, Winokur A.
    Synapse; 1988 Jul; 2(5):546-57. PubMed ID: 2973147
    [Abstract] [Full Text] [Related]

  • 17. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS.
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [Abstract] [Full Text] [Related]

  • 18. Dopamine D4 receptors elevated in schizophrenia.
    Seeman P, Guan HC, Van Tol HH.
    Nature; 1993 Sep 30; 365(6445):441-5. PubMed ID: 8413587
    [Abstract] [Full Text] [Related]

  • 19. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.
    Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ.
    Neuropsychopharmacology; 1998 Dec 30; 19(6):472-80. PubMed ID: 9803423
    [Abstract] [Full Text] [Related]

  • 20. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
    Pizzolato G, Cagnin A, Rossato A, Chierichetti F, Fabbri M, Dam M, Ferlin G, Battistin L.
    Adv Neurol; 1996 Dec 30; 69():467-73. PubMed ID: 8615167
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.